Form 4: Alnylam R&D Chief Sells Shares Post-RSU Vesting

Alnylam Pharmaceuticals' EVP Chief R&D, Pushkal Garg, sold 4,627 shares of common stock following the vesting of 1,908 restricted stock units, all executed under a pre-arranged 10b5-1 trading plan.

Summary

• Pushkal Garg, EVP Chief R&D at Alnylam Pharmaceuticals, reported transactions on February 27, 2026.
• 1,908 restricted stock units (RSUs) vested, representing the third and final tranche of a grant made on February 27, 2023.
• Following the RSU vesting, Garg sold a total of 4,627 shares of common stock through multiple transactions.
• The sales were executed at weighted average prices ranging from $328.92 to $334.39 per share.
• All transactions were conducted pursuant to a Rule 10b5-1(c) trading plan adopted on November 20, 2025.
• After these transactions, Garg directly owns 22,129 shares, with an additional 431 shares in a managed 401(k) account and 250 shares in a trust (beneficial ownership disclaimed).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While an insider sale occurred, it was pre-planned and routine, indicating no immediate negative implications for the company's prospects, and the executive retains substantial holdings.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1(c) trading plan, indicating a lack of opportunistic timing.
• The officer retains a significant direct ownership of 22,129 shares, plus indirect holdings, demonstrating continued alignment with shareholder interests.
• The vesting of restricted stock units indicates the successful completion of a performance or tenure period.

Negatives

• The sale of 4,627 shares by a key executive could be perceived as a slight negative signal, although mitigated by the 10b5-1 plan.

Risks

• No explicit risks are mentioned in this Form 4 filing. The sale itself, while pre-planned, could be interpreted by some as a minor signal of reduced insider confidence, though this is speculative given the 10b5-1 plan.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that executive stock sales following RSU vesting are a common occurrence in the biotechnology and pharmaceutical industries. Such transactions often serve to cover tax obligations associated with vesting or to diversify personal portfolios, especially when executed under a pre-arranged 10b5-1 trading plan, which is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive stock sales under Rule 10b5-1 plans are a widely accepted and standard practice across publicly traded companies, including those in the biotech sector like Alnylam Pharmaceuticals.
• This mechanism allows insiders to sell shares at predetermined times or prices without being accused of trading on material non-public information.
• For instance, executives at companies such as Regeneron Pharmaceuticals (REGN) or Vertex Pharmaceuticals (VRTX) frequently utilize similar plans for managing their equity compensation and personal finances.
• The volume of shares sold by Pushkal Garg, while notable, represents a portion of his overall holdings and is consistent with typical executive compensation management strategies rather than signaling a significant shift in company outlook.

Related Party Transactions

• The reported transactions involve the EVP Chief R&D, Pushkal Garg, selling company stock, which is a direct related party transaction.
• Additionally, 250 shares are held in a trust where the reporting person's spouse is co-trustee, though beneficial ownership is disclaimed.

Stakeholder Impact

• Shareholders: The sale by a key executive, even if pre-planned, could be viewed with slight caution, but the continued significant holdings suggest ongoing alignment.

Next Steps

• The filing does not explicitly mention any future actions, events, or milestones beyond the reported transactions.

Key Dates

Recommendation

The Form 4 filing details routine insider transactions (RSU vesting and subsequent sales) executed under a pre-arranged 10b5-1 plan. This type of transaction is common for executive compensation and personal financial management and does not typically signal a change in the company's fundamental outlook or performance. While an insider sale might otherwise be a minor negative, the pre-planned nature mitigates this concern. The executive retains a substantial stake in the company, indicating continued confidence. Therefore, based solely on this filing, a seasoned investor would likely maintain their current position, as there is no new information to warrant a change in investment strategy.

Keywords

Alnylam Pharmaceuticals, ALNY, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sale, 10b5-1 Plan, Executive Compensation, Biotechnology, Pharmaceuticals